May 18, 2020
The head of the European Union’s medicines agency Guido Rasi said on Monday an initial authorisation for U.S. pharmaceutical company Gilead’s remdesivir as a COVID-19 treatment could be granted in coming days.
The European Medicines Agency (EMA) has already recommended the compassionate use of remdesivir, which allows a drug to be administered to patients even before it has been fully authorised.
“It might be that a conditional market authorisation can be issued in the coming days,” Rasi told a hearing in the EU Parliament in Brussels.
Apart from remdesivir, Rasi said other possible treatments against COVID-19 that may be available fast are those based on monoclonal antibodies, which can “neutralize” the new coronavirus (SARS-CoV-2) that causes the illness COVID-19.
Also read: Coronavirus vaccine: Multiple trials show positive results but concerns about timeframe remain
Also read: Coronavirus vaccine update: Moderna, Novavax lead race; Chinese firm builds largest vaccine plant
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.